Physician profile
Tamara Brown
NPI 1942569785
$1,458.75
in general payments reported to CMS, 2019-2025
15 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $14.08 · 2023: $219 · 2024: $959 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305 · Education: $17.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.70 |
| Education | $17.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $758.28 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $124.56 | 2024 | Voquezna |
| Alexion Pharmaceuticals, INC. | $122.27 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.16 | 2024-2025 | Entyvio, Eohilia |
| Fresenius Kabi USA, LLC | $68.69 | 2023 | Idacio |
| Lilly USA, LLC | $57.36 | 2023-2024 | Omvoh |
| Genzyme Corporation | $33.15 | 2024 | |
| Merck Sharp & Dohme LLC | $28.89 | 2024 | Dificid |
| Pfizer INC. | $27.42 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $26.72 | 2024 | Dupixent |
| Gilead Sciences, INC. | $24.15 | 2023 | |
| Janssen Biotech, INC. | $22.26 | 2024 | Stelara |
| Celltrion USA INC. | $17.70 | 2023 | Yuflyma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.06 | 2024 | Xifaxan |
| Medtronic, INC. | $14.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.